Sarepta Therapeutics (SRPT) shares fell as much as 4.8% in premarket trading Monday, poised to extend losses for a second ...

Sarepta Therapeutics traded lower on Monday, extending a slide as the company took the unusual step of refusing a Food and ...

Sarepta has refused to suspend all dosing of its gene therapy for Duchenne muscular dystrophy, Elevidys, defying a clinical ...

In addition, Sarepta Therapeutics (SRPT) plummeted more than -35% after the company said another patient had died from acute ...

Sarepta says it will continue to ship Elevidys despite FDA requests that it stop shipments of the Duchenne muscular dystrophy gene therapy, while Wall Street awaits earnings Monday from Verizon.

Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.

While the North Chicago, Illinois-based healthcare giant estimated its adjusted diluted earnings per share for Q3 could reach $1.28 - $1.32 compared to $1.33 in the consensus, its full-year outlook ...

Gaza saw its deadliest day yet for aid-seekers in over 21 months of war as more than 80 Palestinians were killed while trying ...

Shares in Europe and Asia are mostly higher after U.S. stocks claimed their third straight winning week. U.S. futures ...

"While COPD remains the third leading cause of death worldwide, patients and families have limited treatment options for ...

Resorts in Spain and Portugal are the most popular destinations for UK holidaymakers this summer, according to a new report.